ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline and London’s new Francis Crick Institute have agreed to co-develop treatments for diseases including HIV, malaria, and cancer. Both parties will contribute 10 researchers to the collaboration, which by 2016 aims to have up to 15 projects. GSK will provide the partnership with access to its library of 2 million compounds with interesting pharmaceutical properties. The two will work together in GSK’s R&D center in Stevenage, just north of London, and also at Crick’s $1 billion center after it opens in London later this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X